Analyst Price Targets — ALLO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 14, 2026 11:44 am | — | Bernstein | $3.85 | $3.06 | TheFly | Allogene Therapeutics price target raised to $3.85 from $1.60 at Bernstein |
| April 14, 2026 11:28 am | — | Robert W. Baird | $9.00 | $3.06 | TheFly | Allogene Therapeutics price target raised to $9 from $7 at Baird |
| May 16, 2024 6:44 am | Debjit Chattopadhyay | H.C. Wainwright | $9.00 | $2.98 | StreetInsider | Allogene (ALLO) PT Lowered to $9 at H.C. Wainwright |
| May 14, 2024 7:33 am | Kalpit Patel | B.Riley Financial | $7.00 | $2.90 | StreetInsider | Allogene (ALLO) PT Lowered to $7 at B.Riley |
| June 13, 2022 11:19 pm | Jack Allen | Robert W. Baird | $11.00 | $9.74 | Pulse 2.0 | Allogene Therapeutics (ALLO) Stock Price: $11 Target From Baird |
| January 3, 2022 12:00 am | Michael Schmidt | Guggenheim | $35.00 | $15.29 | TheFly | Allogene Therapeutics price target lowered to $35 from $40 at Guggenheim |
| December 3, 2021 12:00 am | John Newman | Canaccord Genuity | $55.00 | $17.62 | TheFly | Allogene Therapeutics clinical hold could be lifted shortly, says Canaccord |
| October 8, 2021 12:00 am | Anthony Butler | Roth Capital | $35.00 | $13.13 | TheFly | Allogene Therapeutics price target lowered to $35 from $60 at Roth Capital |
| October 8, 2021 12:00 am | Jason Gerberry | Bank of America Securities | $32.00 | $13.13 | StreetInsider | Allogene (ALLO) PT Lowered to $32 at BofA Securities |
| October 8, 2021 12:00 am | Mark Breidenbach | Oppenheimer | $40.00 | $13.13 | TheFly | Allogene Therapeutics price target lowered to $40 from $44 at Oppenheimer |
Latest News for ALLO
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that Geoffrey Parker, Executive Vice President and Chief Financial Officer, will retire effective November 6, 2026.
Deutsche Bank AG bought a new stake in Allogene Therapeutics, Inc. (NASDAQ: ALLO) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 281,949 shares of the company's stock, valued at approximately $586,000. Deutsche Bank AG owned about 0.08% of Allogene
Connor Clark and Lunn Investment Management Ltd. purchased a new position in shares of Allogene Therapeutics, Inc. (NASDAQ: ALLO) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 322,827 shares of the company's stock, valued at approximately $671,000. Connor Clark
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in the following upcoming investor conference in September.
Cema-cel produced MRD clearance in 58.3% of treated patients versus 16.7% under observation. The 97.7% median ctDNA reduction by day 45 shows substantial early biological activity. FDA RMAT and Fast Track designations support the development strategy but do not prove durable efficacy.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ALLO.
U.S. House Trading
No House trades found for ALLO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.